Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative?

Simply Wall St.11:29

Disc Medicine, Inc. reported a first-quarter 2026 net loss of US$63.5 million, with basic loss per share from continuing operations of US$1.65, while also preparing to present new data from multiple ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636093077?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-17 11:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636093077","market":"nz","top_or_hot":-1,"title":"Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Disc Medicine, Inc. reported a first-quarter 2026 net loss of US$63.5 million, with basic loss per share from continuing operations of US$1.65, while also preparing to present new data from multiple ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/should-disc-medicines-rally-mf-data-and-wider-pipeline-revea\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-17 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/should-disc-medicines-rally-mf-data-and-wider-pipeline-revea><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Disc Medicine, Inc. reported a first-quarter 2026 net loss of US$63.5 million, with basic loss per share from continuing operations of US$1.65, while also preparing to present new data from multiple ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/should-disc-medicines-rally-mf-data-and-wider-pipeline-revea\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/should-disc-medicines-rally-mf-data-and-wider-pipeline-revea","article_id":"2636093077","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/should-disc-medicines-rally-mf-data-and-wider-pipeline-revea","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636093077","pubTimestamp":1778988583,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Disc Medicine, Inc. reported a first-quarter 2026 net loss of US$63.5 million, with basic loss per share from continuing operations of US$1.65, while also preparing to present new data from multiple hematology programs at the European Hematology Association Congress.\nThe upcoming RALLY-MF phase 2 and bitopertin data presentations at a major hematology meeting highlight how much of Disc Medicine’s story now hinges on clinical progress rather than current earnings.\nNext, we’ll examine how the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","IRON":"Disc Medicine"},"translate_title":"Disc Medicine的反弹-MF数据和更广泛的渠道是否应该揭示IRON叙事的关键转折点？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRON":1.5},"content_text":"Disc Medicine, Inc. reported a first-quarter 2026 net loss of US$63.5 million, with basic loss per share from continuing operations of US$1.65, while also preparing to present new data from multiple hematology programs at the European Hematology Association Congress. The upcoming RALLY-MF phase 2 and bitopertin data presentations at a major hematology meeting highlight how much of Disc Medicine’s story now hinges on clinical progress rather than current earnings. Next, we’ll examine how the upcoming RALLY-MF phase 2 data presentation could shape Disc Medicine’s investment narrative despite recent share price weakness. Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementWhat Is Disc Medicine's Investment Narrative?To own Disc Medicine today, you really have to buy into the idea that its hematology platform, not current earnings, will eventually justify the company’s growing cash burn. The latest quarter underlined that trade-off: a wider net loss of US$63.5 million and higher loss per share, paired with preparations to showcase fresh data across several programs at the European Hematology Association Congress. In the near term, the most important catalyst is still clinical: the upcoming RALLY-MF phase 2 readout for DISC-0974 in myelofibrosis anemia, alongside ongoing bitopertin work after the FDA’s Complete Response Letter. The new EHA data presentations fit right into that story by keeping the pipeline in focus, but they do not change the fact that rising losses and insider selling remain front-of-mind risks. However, investors should also weigh how rising losses and insider selling could reshape the story.\n\nDespite retreating, Disc Medicine's shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesIRON 1-Year Stock Price Chart With 1 fair value estimate from the Simply Wall St Community clustering at about US$101, you are seeing a single, confident view rather than a spread of opinions. Set against the widening losses and reliance on upcoming trial data, it is a reminder that many other investors may be thinking very differently about what Disc’s pipeline is worth.Explore another fair value estimate on Disc Medicine - why the stock might be worth just $101.09!Reach Your Own ConclusionDisagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Disc Medicine research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free Disc Medicine research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Disc Medicine's overall financial health at a glance.Seeking Other Investments?Every day counts. These free picks are already gaining attention. See them before the crowd does:Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636093077","isCrawlerRequest":true}